SAN FRANCISCO -- Two mainstream devices for percutaneous left atrial appendage (LAA) closure continued to lead to similar clinical outcomes in the SWISS-APERO trial. Among patients randomized to the ...
Boston Scientific has shared a duo of positive data readouts from two separate trials evaluating its Watchman FLX left atrial appendage closure (LAAC) device in non-valvular atrial fibrillation (AF) ...
Boston Scientific, Inc. BSX recently announced receiving the FDA approval for the latest-generation WATCHMAN FLX Pro Left Atrial Appendage Closure (LAAC) Device. The latest device is intended to ...
Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global clinical trial for its WATCHMAN FLX Left Atrial Appendage Closure (“LAAC”) device ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results